Life Sciences companies can now apply a new approach to assessing the “affectability” (or dollar value) of the economic potential of digital health assets in specific therapeutic areas (TAs) across the patient journey: prevention/early diagnosis, intervention and monitoring.
By assessing digital opportunities and avoidable costs through a TA lens, they can identify hidden pockets of value they have likely overlooked. They can define a value-creation strategy, based on a differentiated portfolio of digital assets. And they can make more strategic investment decisions that help improve patient outcomes, business performance and competitive advantage.
Comment submitted
Submitted comment may not display automatically.